Infantile melanoma-A triple threat: Diagnosis and management

Annals of Plastic Surgery

Volumn 67, Issue 1, 2011, Pages 85-89

  Lambie, Milena ^a   Nadler, Chad ^b   Glat, Paul ^b,c   Van Duzer, Scott ^c   Halligan, Gregory ^c   Geller, Evan ^c  

^a PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

Author keywords

chemoimmunotherapy; congenital melanocytic nevus; infantile melanoma; pediatric melanoma; sentinel lymph node biopsy

Indexed keywords

CASE REPORT; DELAYED DIAGNOSIS; FEMALE; HUMAN; INFANT; MALE; MELANOMA; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REVIEW;

COMBINED MODALITY THERAPY; DELAYED DIAGNOSIS; FEMALE; HUMANS; INFANT; MALE; MELANOMA;

EID: 79959707077     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/SAP.0b013e3181e0fcbc     Document Type: Conference Paper

References (43)

1. Makkar HS, Frieden IJ. Congenital melanocytic nevi: an update for the pediatrician. Curr Opin Pediatr. 2002;14:397-403. (Pubitemid 34774923)
2. Reis LA, Smith MA, Gurney JG, et al, eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995 Bethesda, MD: National Cancer Institute, SEER Program, National Institutes of Health 1999. NIH Pub. No. 99-4649.
3. Ceballos PI, Ruiz-Maldonado R, Mihm MC. Melanoma in children. N Engl J Med. 1995;332:656-662.
4. Strouse JJ, Fears TR, Tucker MA, et al. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol. 2005;23:4735-4741. (Pubitemid 46224077)
5. Trozak DJ, Rowland WD, Hu F. Metastatic melanoma in prepubertal children. Pediatrics. 1975;55:191-204.
6. Dargeon HW, Eversole J, Del Duca V. Malignant melanoma in an infant. Cancer. 1950;3:299-306.
7. Richardson SK, Tannous ZS, Mihm MC. Congenital and infantile melanoma: review of the literature and report of an uncommon variant, pigmentsynthesizing melanoma. J Am Acad Dermatol. 2002;47:77-90.
8. Barnhill RL, Fleischli M. Histologic features of congenital melanocytic nevi in infants 1 year of age or younger. J Am Acad Dermatol. 1995;33:780-785.
9. Valiukeviciene S, Miseviciene I, Gollnick H. The prevalence of common acquired melanocytic nevi and relationship with skin type characteristics and sun exposure among children in Lithuania. Arch Dermatol. 2005;141:579-586. (Pubitemid 40656061)
10. Walton RG, Jacobs AH, Cox AJ. Pigmented lesions in newborn infants. Br J Dermatol. 1976;95:389-396.
11. Williams ML. Controversies in pediatric dermatology: congenital nevi. Pediatr Dermatol. 2000;17:75-83.
12. Marghoob AA, Schoenbach SP, Kopf AW, et al. Large congenital melanocytic nevi and the risk for the development of malignant melanoma: a prospective study. Arch Dermatol. 1996;132:170-175. (Pubitemid 26058506)
13. Quaba AA, Wallace AF. The incidence of malignant melanoma (0 to 15 years of age) arising in "large" congenital nevocellular nevi. Plast Reconstr Surg. 1986;78:174-181.
14. Greenley PW. Incidence of malignancy in giant pigmented nevi. Plast Reconstr Surg. 1965;36:26-37.
15. Ka VS, Dusza SW, Halpern AC, et al. The association between large congenital melanocytic naevi and cutaneous melanoma: preliminary findings from an internet-based registry of 379 patients. Melanoma Res. 2005;15:61-67. (Pubitemid 40354475)
16. Kaplan EN. The risk of malignancy in large congenital nevi. Plast Reconstr Surg. 1974;53:421-428.
17. Demierre MF, Chung C, Meller DR, et al. Early detection of thick melanomas in the United States. Arch Dermatol. 2005;141:745-750.
18. Urist MM, Soong S-J. Melanoma and cutaneous malignancies. In: Townsend CM, Mattox KM, Evers BM, Beauchamp RD, eds. Sabiston Textbook of Surgery. 17th ed. 2004;781-802.
19. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol. 2009;27:6199-6206.
20. Lerman R, Murray D, O'Hara J, et al. Malignant melanoma of childhood. Cancer. 1970;25:436-449.
21. Moss AL, Briggs JC. Cutaneous malignant melanoma in the young. Br J Plast Surg. 1986;39:537-541. (Pubitemid 17205650)
22. Rao BN, Hayes FA, Pratt CB, et al. Malignant melanoma in children: its management and prognosis. J Pediatr Surg. 1990;25:198-203. (Pubitemid 20046188)
23. Abai B, Thayer D, Glat PM. The use of a dermal regeneration template (Integra) for acute resurfacing and reconstruction of defects created by excision of giant hairy nevi. Plast Reconstr Surg. 2004;114:162-168. (Pubitemid 39195643)
24. Gibbs P, Moore A, Robinson W, et al. Pediatric melanoma: are recent advances in the management of adult melanoma relevant to the pediatric population. J Pediatr Hematol Oncol. 2000;22:428-432. (Pubitemid 33599750)
25. Zuckerman R, Maier JP, Guiney WB, et al. Pediatric melanoma: confirming the diagnosis with sentinel node biopsy. Ann Plast Surg. 2001;46:394-399. (Pubitemid 32319677)
26. Arons MS, Hurwitz S. Congenital nevocellular nevus: a review of the treatment controversy and a report of 46 cases. Plast Reconstr Surg. 1983; 72:355-365. (Pubitemid 13040072)
27. Balch CM, Soong SJ, Merrick IR, et al. Long-term results of a multiinstitutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7:87-97. (Pubitemid 30164676)
28. Alexander A, Samlowski WE, Grossman D, et al. Metastatic melanoma: risk of transplacental metastases in the infant. J Clin Oncol. 2003;21:2179-2186. (Pubitemid 46606367)
29. Shah NC, Gerstle JT, Stuart M, et al. Use of sentinel lymph node biopsy and high-dose interferon in pediatric patients with high-risk melanoma: the Hospital for Sick Children experience. J Pediatr Hematol Oncol. 2006;28:496-500. (Pubitemid 44257995)
30. Spatz A, Ruiter D, Hardmeier T, et al. Melanoma in childhood: an EORTCMCG multicenter study on the clinicopathological aspects. Int J Cancer. 1996;68:317-324. (Pubitemid 26384134)
31. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I and II melanoma patients. J Clin Oncol. 1999;17:976-983. (Pubitemid 29109331)
32. Flaherty LE, Thompson JA, Tuthill RJ. Phase III trial of high dose interferon alfa-2b vs cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high risk melanoma: the Southwest Oncology Group (SWOG) 2004-ongoing trial.
33. Zapas JL, Coley HC, Beam SL, et al. The risk of regional lymph node metastases in patients with melanoma less than 1.0 mm thick: recommendations for sentinel lymph node biopsy. J Am Coll Surg. 2003;197:403-407. (Pubitemid 38373299)
34. Balch CM, Soong S, Barolucci AA. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255-266. (Pubitemid 26307468)
35. Pacella SJ, Lowe L, Bradford C, et al. The utility of sentinel lymph node biopsy in head and neck melanoma in the pediatric population. Plast Reconstr Surg. 2003;112:1257-1265. (Pubitemid 43933910)
36. Berg P, Lindelof B. Differences in malignant melanoma between children and adolescents. Arch Dermatol. 1997;133:295-297. (Pubitemid 27142319)
37. Jafarian F, Hatami A, Kokta V, et al. Malignant melanoma in children and adolescents: review of 13 cases. Pediatr Dermatol. 2004;21:394.
38. Melnik MK, Urdaneta LF, Al-Jurf AS, et al. Malignant melanoma in childhood and adolescence. Am Surg. 1986;52:142-147. (Pubitemid 16160016)
39. Wu SJ, Lambert DR. Melanoma in children and adolescents. Pediatr Dermatol. 1997;14:87-92. (Pubitemid 27193833)
40. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alpha-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7-17. (Pubitemid 26019991)
41. Anderson C, Buzaid A, Legha S. Systemic treatment of advanced cutaneous melanoma. Oncology. 1995;9:1149-1158.
42. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316: 889-897. (Pubitemid 17041979)
43. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukins 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116. (Pubitemid 29318842)